Navigation Links
International Human Rights Day Recognized by Terasem Movement, Inc.'s Third Annual Colloquium on the Law of Transbeman Persons
Date:12/3/2007

Public Invited Via Conference Call on December 10, 2007

SPACE COAST, Fla., Dec. 3 /PRNewswire-USNewswire/ -- Terasem Movement, Incorporated announced today that its Third Annual Colloquium on the Law of Transbeman Persons, in celebration of International Human Rights Day, will be held December 10, 2007 along Florida's Space Coast. A transbeman is a bio-electronic human transitioning between flesh and computerized substrate.

The colloquia are open to the public via real-time conference call and blogging and will be archived online for free public access. The public is invited to call a toll-free conference-call dial-in line from 9:00 a.m. - 5:00 p.m. EST. Callers within the continental U.S. and Canada may dial 1-877-879-6207; other countries: (00+1) 1-719-325-4775 or access the blog at: http://acceleratingfuture.com/michael/blog/.

Colloquium presentations are designed for a 15-20 minute delivery, followed by a 20-minute discussion period amongst attendees. Additional questions from the worldwide audience will also be invited. Presentations will also be available on the Colloquium's website at: http://www.terasemcentral.org/TL/2007ColloquiumProgram.html.

This year's speakers by order of presentation are: Dr. Marvin Minsky, MIT, Author: The Emotion Machine; David R. Koepsell, J.D., Ph.D., Yale Interdisciplinary Center for Bioethics; William Sims Bainbridge, Ph.D., National Science Foundation; Linda MacDonald-Glenn, J.D., LLM, Alden March Bioethics Institute and University of Vermont College of Nursing and Health Sciences; Max More, Ph.D., Co-founder of the Extropy Institute; Sebastian Sethe, Sheffield Institute of Biotechnological Law & Ethics; R. Michael Perry, Author: Toward Self-Optimization of Machine; and Prof. Gene Natale, J.D., Keiser University.

Real-ti
'/>"/>

SOURCE Terasem Movement Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
3. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
4. Arrow International Files and Mails Definitive Proxy Materials
5. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
6. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
7. Viragen International to Reverse Split Its Common Stock
8. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
9. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Biosafety and Biosecurity International Conference 2007 to be held in Abu Dhabi from November 12 to 14
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4
Other Biology Technology:measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 2measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 3measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 4measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 5measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 6measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 7measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 8measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 9measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 10measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 11measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 12measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 13measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 14measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 15Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 2Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 3Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 4Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 5Protocol for GenomePlex Whole Genome Amplification from Plant 2Protocol for GenomePlex Whole Genome Amplification from Plant 3Protocol for GenomePlex Whole Genome Amplification from Plant 4Protocol for GenomePlex Whole Genome Amplification from Plant 5Protocol for GenomePlex Whole Genome Amplification from Plant 6
Breaking Biology News(10 mins):Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 3Successful stem cell therapy for treatment of eye disease 2Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 1Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 2Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 3Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 1Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 2Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 3Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 4Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 5Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 6Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 7Regences Social Media Web Site Gets a Facelift 60731 1Regences Social Media Web Site Gets a Facelift 60731 2